Lyon (France), February 13, 2026 – Valneva SE  (Nasdaq: VALN; Euronext Paris: VLA), a specialty vacc...


Lyon (France), February 13, 2026 – Valneva SE  (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company’s single‑dose chikungunya vaccine, IXCHIQ®, the United Kingdom’s (UK) Commission on Human Medicines (CHM) has updated its recommendations for use of the vaccine.   The updated Prescribing Information (PI) will reflect these recommendations, which now include a restriction for individuals over 60 years of age, for people with specified health conditions, as well as timing of vaccination prior to travel. For further details please refer to this Link.  The MHRA confirmed that the benefit–risk profile of IXCHIQ® remains favorable for individuals aged 18 to 59 years who are at risk of chikungunya infection and do not have the contraindicated underlying medical conditions.  The update follows MHRA’s temporary suspension on the use of IXCHIQ® in older individuals1, which was based on reports of serious adverse events (SAEs), mainly in elderly people with significant underlying medical conditions during an outbreak vaccination campaign on the French island of La Reunion.  Valneva is committed to upholding the highest safety standards and will continue monitoring post marketing safety data of IXCHIQ® and work in a collaborative way with all relevant authorities to potentially further update recommendations and restrictions of use, if justified.  About ChikungunyaChikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years2.  In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas3. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas3 and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem4.    About Valneva SEWe are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced tetravalent Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at www.valneva.com. Valneva Investor and Media ContactsLaetitia Bachelot-FontaineVP Global Communications & European Investor RelationsM +33 (0)6 4516 7099laetitia.bachelot-fontaine@valneva.com        Joshua Drumm, Ph.D.VP Global Investor RelationsM +001 917 815 4520joshua.drumm@valneva.com Forward-Looking Statements  This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to regulatory approval of product candidates and review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.    1 https://www.gov.uk/drug-safety-update/ixchiq-chikungunya-vaccine-temporary-suspension-in-people-aged-65-years-or-older    [2] Reemergence of Chikungunya Virus    [3] Vaccine and Therapeutic Options To Control Chikungunya Virus    [4] Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in the Region of the Americas (who.int)   

            
        2026_02_13_IXCHIQ_MHRA_Update_PR_EN_Final
      
      
 
            

VALN

Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Lyon (France), February 13, 2026 – Valneva SE  (Nasdaq: VALN; Euronext Paris: VLA), a specialty vacc...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Valneva&#039;s IXCHIQ® chikungunya vaccine received updated recommendations from the UK CHM, restricting usage for older adults. The vaccine remains favorable for younger adults, beneficial amidst rising chikungunya cases due to climate concerns. This may enhance market confidence in Valneva&#039;s potential revenue streams.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>UK CHM updates recommendations for Valneva&#039;s IXCHIQ® chikungunya vaccine.</li><li>Restrictions now apply for individuals over 60 and specific health conditions.</li><li>IXCHIQ® deemed favorable for adults aged 18-59 without contraindications.</li><li>The vaccine&#039;s monitoring will continue to ensure safety standards.</li><li>Chikungunya virus cases are expected to rise due to climate change.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Valneva SE (VALN)</strong>: Valneva&#039;s IXCHIQ® regulatory updates could influence sales projections.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news fits into &#039;Corporate Developments&#039; due to the regulatory update influencing the marketing and deployment of a key product. The adjusted guidance and ongoing monitoring signify Valneva&#039;s proactive approach in navigating public health challenges, potentially strengthening its market position.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Market response to safety updates could influence investor sentiment significantly.</li><li>Potential increases in international vaccination demand may boost VALN&#039;s sales.</li><li>Observations of adverse events could impact IXCHIQ®&#039;s market perception.</li><li>Collaboration with health agencies for safety could enhance corporate reputation.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Valneva&#039;s IXCHIQ® is a single-dose chikungunya vaccine.</li><li>New recommendations apply restrictions based on age and health conditions.</li><li>60+ age group has increased risks based on serious adverse events.</li><li>Over 3.7 million chikungunya cases reported in the Americas from 2013 to 2023.</li><li>WHO regards chikungunya as a major public health problem.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy VALN with a short-term horizon; expected revenue growth post-regulatory response.</p>
  </section>
</section>


<article>
    <h2>Valneva Updates IXCHIQ® Vaccine Recommendations in the UK</h2>
    <p>Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a company specializing in vaccines, has announced significant updates regarding its chikungunya vaccine, IXCHIQ®. The UK's Commission on Human Medicines (CHM) has revised its recommendations following a thorough review of the benefits and risks associated with IXCHIQ®. The new guidelines come with specific restrictions for individuals over 60 years and those with specified health conditions, highlighting the urgency for travelers considering vaccination.</p>

    <section>
        <h3>Updated Recommendations for IXCHIQ®</h3>
        <p>The revised prescribing information (PI) will encompass:</p>
        <ul>
            <li>Restrictions for individuals aged 60 and older.</li>
            <li>Guidelines for people with specific underlying health conditions.</li>
            <li>Timing recommendations for vaccination prior to travel.</li>
        </ul>
        <p>The UK Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that the benefit-risk profile for IXCHIQ® remains favorable for individuals aged 18 to 59, who are at risk of chikungunya infection and do not possess contraindicated medical conditions.</p>
    </section>

    <section>
        <h3>Context of the Update</h3>
        <p>This update follows the MHRA's temporary suspension of IXCHIQ® for older individuals, a decision prompted by reports of serious adverse events (SAEs) in elderly patients with significant underlying health conditions during an outbreak vaccination campaign in La Reunion, France. Valneva is dedicated to maintaining high safety standards and will continue to monitor the post-marketing safety data for IXCHIQ®.</p>
        <p>Officials from Valneva express their commitment to collaborating with the authorities to ensure that recommendations regarding IXCHIQ® are updated if justified.</p>
    </section>

    <section>
        <h3>About Chikungunya Virus</h3>
        <p>Chikungunya virus (CHIKV) is a mosquito-borne viral disease transmitted primarily by infected Aedes mosquitoes. The disease is known to cause:</p>
        <ul>
            <li>Fever</li>
            <li>Severe joint and muscle pain</li>
            <li>Headache</li>
            <li>Nausea</li>
            <li>Fatigue</li>
            <li>Rash</li>
        </ul>
        <p>Joint pain caused by chikungunya can be debilitating, lasting from weeks to years. Since its resurgence in 2004, chikungunya has been identified in over 110 countries, with more than 3.7 million cases reported across the Americas between 2013 and 2023. The economic and medical burden of this disease is significant, and the World Health Organization (WHO) has flagged it as a major public health concern, particularly as climate change facilitates the geographical spread of mosquito vectors.</p>
    </section>

    <section>
        <h3>About Valneva SE</h3>
        <p>Valneva SE is recognized as a leading specialty vaccine company focused on developing, manufacturing, and commercializing vaccines that address unmet medical needs. With a strong emphasis on innovative vaccine solutions, including first-, best-, or only-in-class candidates, Valneva has successfully advanced numerous vaccines from early research to market. The company currently markets three proprietary travel vaccines.</p>
        <p>The revenue generated from its commercial operations fuels the advancement of its vaccine pipeline, which includes a Lyme disease vaccine candidate partnered with Pfizer and candidates against Zika and Shigella virus threats, among others. For more information, please visit <a href="http://www.valneva.com">valneva.com</a>.</p>
    </section>

    <section>
        <h3>Contact Information</h3>
        <p>For investor and media inquiries, please reach out to:</p>
        <ul>
            <li><strong>Laetitia Bachelot-Fontaine</strong>, VP Global Communications & European Investor Relations, Mobile: +33 (0)6 4516 7099, Email: <a href="mailto:laetitia.bachelot-fontaine@valneva.com">laetitia.bachelot-fontaine@valneva.com</a></li>
            <li><strong>Joshua Drumm, Ph.D.</strong>, VP Global Investor Relations, Mobile: +001 917 815 4520, Email: <a href="mailto:joshua.drumm@valneva.com">joshua.drumm@valneva.com</a></li>
        </ul>
    </section>
    
    <section>
        <h3>Forward-Looking Statements</h3>
        <p>This article contains forward-looking statements regarding Valneva and its business, including compliance with regulatory approvals and the ongoing development of product candidates. Investors should note that actual performance may differ significantly from these expectations due to numerous risks and uncertainties involving vaccine production, clinical trials, and market conditions.</p>
    </section>
</article>

Valneva's IXCHIQ® chikungunya vaccine received updated recommendations from the UK CHM, restricting usage for older adults. The vaccine remains favorable for younger adults, beneficial amidst rising chikungunya cases due to climate concerns. This may enhance market confidence in Valneva's potential revenue streams.

Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News